pirfenidone has been researched along with Pneumonia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Bo, C; Jia, Q; Li, M; Tang, Q; Xing, C; Zhang, Z | 1 |
| Abdelmoneim, AM; Alanazi, MM; Baioumy, B; El-Shafey, RS; Elshazly, AME; Faruk, EM; Hussein, AYA; Mersal, EA; Mogahed, MM; Morsi, AA | 1 |
| Aguilar-Medina, S; Alva-Lopez, LF; Cazzola, M; Domínguez-Arellano, S; Escobar-Alvarado, JC; Falfán-Valencia, R; Matera, MG; Montiel-Lopez, F; Olaya-López, E; Pérez-Rubio, G; Poo, JL; Ramírez-Venegas, A; Sansores, RH; Zavaleta-Martínez, EO | 1 |
| Ali, MF; Anderson, DK; Aubry, MC; Carmona, EM; Dasari, H; Egan, AM; Kottom, TJ; Limper, AH; Peikert, T; Shaughnessy, GF; Van Keulen, VP; Yi, ES | 1 |
| Cheng, X; Han, X; Li, J; Yu, H; Yu, L; Zhang, X | 1 |
| Miao, K; Tian, X; Xu, W; Xu, Y; Zhang, L; Zhang, Y | 1 |
| Cao, ZJ; Dai, HP; Han, ZF; Li, BC; Li, ZG; Liu, Y; Pang, JL; Qi, XM; Song, MY; Wang, C; Wang, J; Yang, PR; Zhang, XR; Zhang, Z | 1 |
| Ghazi-Khansari, M; Heidari, MR; Iranpour, M; Mandegary, A; Pourgholamhossein, F; Pourgholi, L; Pournamdari, M; Poursalehi, HR; Rasooli, R; Samareh-Fekri, M | 1 |
| Dai, M; Hu, C; Hu, Y; Li, H; Li, Q; Li, Y; Liu, S; Long, Y; Mao, Z; Pan, P; Song, C; Su, X; Tan, H; Wu, D; Zhang, L | 1 |
| Aoki, Y; Kato, M; Kojo, Y; Onoue, S; Seto, Y; Yamada, S | 1 |
| Aebischer, O; Benmachiche, M; Bonjour, T; Carrel, G; Castioni, J; Cosma-Rochat, M; Fournier, J; Gachoud, D; Gagliano, M; Giger, A; Greiser, J; Lamy, O; Méan, M; Mieville, A; Rouiller Larpin, N; Tusgul, S; Voruz, S; Wenger, N | 1 |
| Chan, HK; Leung, SS; Onoue, S; Seto, Y; Suzuki, G | 1 |
| Case, N; Chapman, RW; Crawley, Y; Egan, RW; Fine, J; Hey, JA; Kreutner, W; Kung, T; Minnicozzi, M; Spond, J; Wang, P | 1 |
1 review(s) available for pirfenidone and Pneumonia
| Article | Year |
|---|---|
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Squamous Cell; Glucocorticoids; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Male; Nivolumab; Pneumonia; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyridones; Quinolines; Retrospective Studies | 2021 |
1 trial(s) available for pirfenidone and Pneumonia
| Article | Year |
|---|---|
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.
Topics: COVID-19; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Phenotype; Pneumonia; Pyridones | 2023 |
11 other study(ies) available for pirfenidone and Pneumonia
| Article | Year |
|---|---|
Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways.
Topics: Animals; Fibrosis; Hydroxyproline; Interleukin-18; Janus Kinase 2; Macrophages; Pneumonia; Pulmonary Fibrosis; Pyridones; Rats; RNA, Messenger; Signal Transduction; Silicosis; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vimentin | 2022 |
Modeling the Effects of Cypermethrin Toxicity on Ovalbumin-Induced Allergic Pneumonitis Rats: Macrophage Phenotype Differentiation and p38/STAT6 Signaling Are Candidate Targets of Pirfenidone Treatment.
Topics: Alveolitis, Extrinsic Allergic; Animals; Asthma; Dexamethasone; Inflammation; Macrophages; Male; Ovalbumin; p38 Mitogen-Activated Protein Kinases; Phenotype; Pneumonia; Rats; Rats, Wistar | 2023 |
Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis.
Topics: Antigens; B-Lymphocytes; Cell Aggregation; Cell Movement; Cell Proliferation; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Inflammation Mediators; Interleukin-6; Pneumonia; Pyridones; src-Family Kinases; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2021 |
Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Male; Pneumonia; Pyridones | 2021 |
Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A.
Topics: Animals; Disease Models, Animal; Fibrosis; Inflammation; Interleukin-17; Janus Kinases; Lung; Mice; Mice, Inbred C57BL; Pneumonia; Pyridones; Signal Transduction; Silicon Dioxide; STAT Transcription Factors | 2022 |
Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bronchoalveolar Lavage Fluid; Fibrosis; Gene Expression; Gene Expression Profiling; Herbicides; Hydroxyproline; Lung; Lung Injury; Male; Mice; Organ Size; Oxidative Stress; Paraquat; Pneumonia; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1 | 2018 |
Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Caspase 1; Cell Line; Fibrosis; Inflammasomes; Interleukin-1beta; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pneumonia; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1 | 2018 |
Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Dermatitis, Phototoxic; Lung; Male; Pharmaceutical Solutions; Pneumonia; Powders; Pulmonary Fibrosis; Pyridones; Rats; Rats, Sprague-Dawley | 2013 |
[What is new in 2014 for the specialist in hospital internal medicine? The point of view of university hospital chief residents].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arterial Pressure; Catheterization, Central Venous; Diverticulitis; Emergency Service, Hospital; Hospitals, University; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Internal Medicine; Kidney; Medical Staff, Hospital; Pneumonia; Pulmonary Embolism; Pyridones; Shock, Septic; Sympathectomy; Tumor Necrosis Factor-alpha; Ultrasonography; Venous Thromboembolism; Vitamin B 12 Deficiency; Vitamin E | 2015 |
Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Chromatography, Liquid; Desiccation; Disease Models, Animal; Drug Compounding; Male; Ovalbumin; Particle Size; Peroxidase; Pneumonia; Powders; Pyridones; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Technology, Pharmaceutical | 2016 |
Inhibition of experimental acute pulmonary inflammation by pirfenidone.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Guinea Pigs; Humans; Interleukin-6; Lipopolysaccharides; Male; Mice; Pneumonia; Pulmonary Disease, Chronic Obstructive; Pyridones; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 2003 |